Physician profile
Jeffrey S Rumbyrt
NPI 1295735694
$348,074.96
in general payments reported to CMS, 2019-2025
35 companies · $78K in 2025
The $78K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $18K · 2021: $32K · 2022: $62K · 2023: $62K · 2024: $66K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Consulting Fee: $75K · Travel and Lodging: $22K · Food and Beverage: $8,209 · Education: $84.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,729.50 |
| Consulting Fee | $75,225.82 |
| Travel and Lodging | $21,615.45 |
| Food and Beverage | $8,208.82 |
| Education | $84.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $91,050.87 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $76,379.61 | 2020-2025 | Takhzyro, Cinryze, Eohilia |
| Pharming Healthcare, INC. | $67,056.68 | 2019-2025 | Ruconest |
| Shire North American Group INC | $25,398.65 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18,201.31 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Abbvie INC. | $11,765.88 | 2021-2023 | Rinvoq |
| Csl Behring | $11,748.46 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Ionis Pharmaceuticals, INC. | $9,662.25 | 2025 | Dawnzera |
| Grifols USA, LLC | $8,021.19 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Genentech, INC. | $5,820.49 | 2020 | |
| Dermavant Sciences, INC. | $4,553.39 | 2023-2024 | Vtama |
| Biocryst Pharmaceuticals, INC. | $3,497.75 | 2020-2025 | |
| Cycle Pharmaceuticals INC | $3,119.95 | 2022-2025 | Sajazir |
| Regeneron Pharmaceuticals, INC. | $2,943.75 | 2022 | |
| Genentech USA, INC. | $2,159.23 | 2019-2025 | Xolair |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,992.75 | 2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,295.67 | 2019-2020 | |
| Adare Pharmaceuticals, INC. | $1,103.66 | 2020 | |
| Optinose US, INC. | $841.67 | 2020-2024 | |
| Glaxosmithkline, LLC. | $445.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $307.68 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $233.73 | 2023-2025 | Dupixent |
| Genzyme Corporation | $178.06 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $107.79 | 2019-2021 | |
| Organon LLC | $45.83 | 2025 | Vtama |
| Blueprint Medicines Corporation | $39.59 | 2022-2025 | Ayvakit |
| Galderma Laboratories, L.P. | $32.04 | 2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $26.09 | 2025 | Neffy |
| Leo Pharma INC. | $24.89 | 2022 | |
| Pfizer INC. | $20.67 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rumbyrt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.